Ravi Ananthanarayanan

India’s Tata Steel Europe JV hits roadblock, but it is not a deal-breaker

The opposition from some Thyssenkrupp investors, which may be causing concern, is on the structure of the deal.

Fortis board mulls three different bids, no lucky break in sight

Three offers are on the table now. The valuation of a Fortis share does not materially vary in the offers, but the deal structures are very different.

Fosun-Gland Pharma: The Chinese flag goes up

Is a 74% stake in Chinese hands really that different from an 86.1% stake?

India: Aurobindo Pharma buys Generis in a bid to boost margins in Europe

Aurobindo is paying €135million, or Rs 970 crore, to acquire Generis, a generic drug company, valuing it at 2 times revenue and 10.6 times Ebitda. Aurobindo’s debt is likely to increase because of this acquisition.

India: Tata Steel sells Scunthorpe asset for a song, stock dips

News that Tata Steel Ltd may have sold its European long products business, possibly for less than the price of a cup of coffee, did little to cheer its shareholders.

India: How should one interpret the acquisition of Indulekha by HUL?

How should one interpret the acquisition of a small regional brand by Hindustan Unilever Ltd (HUL)? Last week, it said it will pay Rs.330 crore to acquire the Indulekha and Vayodha ayurvedic personal care brands from the Mosons Group. This amount will be supplemented with a payment of 10% of… Read more »

Strides Arcolab gives India business a boost by acquiring portfolio of drugs from Sun Pharma

Strides Arcolab Ltd’s shareholders seem to think small is beautiful. Its shares gained by 4.6% on Monday after the firm announced over the weekend that it was paying Rs 165 crore to acquire a portfolio of drugs from Sun Pharmaceutical Industries Ltd. These drugs generated a revenue of Rs 92 crore in… Read more »